AU4105985A - Implantable formulations of regulatory peptides with controlled release - Google Patents

Implantable formulations of regulatory peptides with controlled release

Info

Publication number
AU4105985A
AU4105985A AU41059/85A AU4105985A AU4105985A AU 4105985 A AU4105985 A AU 4105985A AU 41059/85 A AU41059/85 A AU 41059/85A AU 4105985 A AU4105985 A AU 4105985A AU 4105985 A AU4105985 A AU 4105985A
Authority
AU
Australia
Prior art keywords
controlled release
regulatory peptides
implantable formulations
implantable
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU41059/85A
Other languages
English (en)
Inventor
Jurgen Kurt Sandow
Heinz-Rudiger Seidel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of AU4105985A publication Critical patent/AU4105985A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU41059/85A 1984-04-11 1985-04-10 Implantable formulations of regulatory peptides with controlled release Abandoned AU4105985A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3413608 1984-04-11
DE19843413608 DE3413608A1 (de) 1984-04-11 1984-04-11 Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
AU4105985A true AU4105985A (en) 1985-10-17

Family

ID=6233259

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41059/85A Abandoned AU4105985A (en) 1984-04-11 1985-04-10 Implantable formulations of regulatory peptides with controlled release

Country Status (12)

Country Link
EP (1) EP0158277A3 (2)
JP (1) JPS60228411A (2)
KR (1) KR850007559A (2)
AU (1) AU4105985A (2)
DE (1) DE3413608A1 (2)
DK (1) DK162385A (2)
ES (1) ES8607732A1 (2)
GR (1) GR850905B (2)
HU (1) HUT40760A (2)
IL (1) IL74848A0 (2)
PT (1) PT80252B (2)
ZA (1) ZA852639B (2)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587626B2 (en) * 1985-07-29 1989-08-24 Wyeth Holdings Corporation Continuous release peptide composition
AU656897B2 (en) * 1990-07-19 1995-02-23 University Of Kentucky Research Foundation, The Drug delivery system involving interaction between protein or polypeptide and hydrophobic biodegradable polymer
US6777386B2 (en) 1996-08-30 2004-08-17 Peptech Limited Sustained peptide-release formulation

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137874A (en) * 1985-07-29 1992-08-11 American Cyanamid Co. Partially coated C10 -C20 fatty acid salts of peptides having molecular weights up to about 5,000
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
AU601736B2 (en) * 1986-05-23 1990-09-20 Sanofi Sante Nutrition Animale Sa Coated veterinary implants
WO1989005138A1 (en) * 1987-12-08 1989-06-15 Mark Chasin Method of forming bioerodible implants for improved controlled drug release
JP2590358B2 (ja) * 1988-03-01 1997-03-12 正雄 五十嵐 子宮内膜症治療用の子宮内又は膣内投与製剤
WO1991006287A1 (en) * 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
EP0723402B1 (en) 1993-08-30 2010-08-18 Baylor College Of Medicine Senescent cell-derived inhibitors of dna synthesis
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6171788B1 (en) 1997-01-28 2001-01-09 The Regents Of The University Of California Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US7138511B1 (en) 1997-01-28 2006-11-21 The Regents Of The University Of California Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6475724B1 (en) 1997-01-28 2002-11-05 The Regents Of The University Of California Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US20040224000A1 (en) * 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
AU2005247943A1 (en) 2004-05-23 2005-12-08 Gerard M. Housey Theramutein modulators
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
ES2569917T3 (es) 2005-06-21 2016-05-13 Xoma (Us) Llc Anticuerpos y fragmentos de los mismos que se unen a IL-1beta
DE602007009045D1 (de) * 2006-01-05 2010-10-21 Med Inst Inc Zein-beschichtete medizinische vorrichtung
EP3124045A3 (en) 2006-12-20 2017-05-03 Xoma (Us) Llc Treatment of il-1 beta related diseases
EP3127549B1 (en) 2007-06-22 2019-12-18 Children's Medical Center Corporation Methods and uses thereof of a fragment of saposin a
EP2214747A2 (en) 2007-11-20 2010-08-11 Cook Incorporated Controlled drug delivery using a zein layer modified with levulinic acid
DK2391650T3 (en) 2007-12-20 2015-01-12 Xoma Us Llc Methods of treating gout
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
CN101669899B (zh) * 2009-09-29 2011-02-02 河北科技大学 玉米蛋白为主要骨架材料或基质的缓释埋植剂及其用途
EP2513137B1 (en) 2009-12-17 2018-02-28 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
EP3165531B1 (en) 2010-03-12 2020-11-25 Children's Medical Center Corporation Immunogenic composition, vaccine, and uses thereof
CN101843577A (zh) * 2010-04-08 2010-09-29 安徽中医学院 以玉米醇溶蛋白为骨架材料的包衣植入剂及制备方法
CN104203275A (zh) 2010-06-09 2014-12-10 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
CN108840912B (zh) 2011-05-11 2023-07-04 儿童医疗中心有限公司 修饰的生物素结合蛋白及其融合蛋白和应用
WO2013028541A1 (en) 2011-08-19 2013-02-28 Children's Medical Center Corporation Vegf-binding protein for blockade of angiogenesis
JP6320300B2 (ja) 2011-12-19 2018-05-09 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー 座瘡を治療するための方法
CA2860226C (en) 2011-12-22 2022-10-18 Randolph S. Watnick Saposin-a derived peptides and uses thereof
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
WO2013106489A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
CA2900008C (en) 2013-02-07 2025-10-07 Children's Medical Center Corporation PROTEIN ANTIGENS THAT CONFER PROTECTION AGAINST COLONIZATION AND/OR PNEUMOCOCCAL DISEASE
US10640574B2 (en) 2013-07-18 2020-05-05 Taurus Biosciences, Llc Humanized antibodies with ultralong complementary determining regions
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
AU2014318579A1 (en) 2013-09-13 2016-04-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
AU2014337385B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Chimeric antigen receptor T cell switches and uses thereof
CN105829349B (zh) 2013-10-15 2023-02-03 斯克利普斯研究所 肽嵌合抗原受体t细胞开关和其用途
KR102455171B1 (ko) 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
EP2977758A1 (en) 2014-07-24 2016-01-27 Université De Nice Sophia Antipolis Methods and kits for monitoring membranous nephropathy
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
EP3283113A4 (en) 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
KR102613430B1 (ko) 2016-10-19 2023-12-18 더 스크립스 리서치 인스티튜트 인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도
US12458705B2 (en) 2018-06-12 2025-11-04 Angiex, Inc. Antibody-oligonucleotide conjugates
JP7765379B2 (ja) 2019-08-12 2025-11-06 ピュリノミア バイオテック， インコーポレイテッド Ｃｄ３９発現細胞のａｄｃｃ標的化を介してｔ細胞媒介性免疫応答を促進及び増強するための方法及び組成物
CA3158893A1 (en) 2019-10-24 2021-04-29 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
CN118251420A (zh) 2021-04-28 2024-06-25 米诺陶治疗公司 人源化嵌合牛抗体和使用方法
WO2023212483A1 (en) 2022-04-29 2023-11-02 Purinomia Biotech, Inc. Methods and compositions for treating eosinophil driven diseases and disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE184774C (2) *
US2895880A (en) * 1955-05-13 1959-07-21 Smith Kline French Lab Sustained release pharmaceutical product
GB935672A (en) * 1960-07-19 1963-09-04 Sterling Drug Inc Sustained release tablet
DE2242844A1 (de) * 1972-08-31 1974-04-11 Wolfgang Joachim Guettner Spruehmittel auf zein-basis
HUT35524A (en) * 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587626B2 (en) * 1985-07-29 1989-08-24 Wyeth Holdings Corporation Continuous release peptide composition
AU656897B2 (en) * 1990-07-19 1995-02-23 University Of Kentucky Research Foundation, The Drug delivery system involving interaction between protein or polypeptide and hydrophobic biodegradable polymer
US6777386B2 (en) 1996-08-30 2004-08-17 Peptech Limited Sustained peptide-release formulation
US7309689B2 (en) 1996-08-30 2007-12-18 Peptech Limited Sustained peptide-release formulation

Also Published As

Publication number Publication date
KR850007559A (ko) 1985-12-07
PT80252B (de) 1987-02-03
ES542045A0 (es) 1986-06-01
ES8607732A1 (es) 1986-06-01
GR850905B (2) 1985-11-25
JPS60228411A (ja) 1985-11-13
DE3413608A1 (de) 1985-10-24
DK162385D0 (da) 1985-04-10
HUT40760A (en) 1987-02-27
EP0158277A2 (de) 1985-10-16
IL74848A0 (en) 1985-07-31
EP0158277A3 (de) 1987-04-29
DK162385A (da) 1985-10-12
ZA852639B (en) 1985-11-27
PT80252A (de) 1985-05-01

Similar Documents

Publication Publication Date Title
ZA852639B (en) Implantable formulations of regulatory peptides with controlled release,and process for their preparation
AU2189588A (en) Artificial skin
AU4897085A (en) Intracanalicular implant
AU587358B2 (en) Control of retroviruses
AU5295890A (en) Preparation of functional human factor viii
AU1828988A (en) Controlled release formulation
EP0282951A3 (en) Controlled release preparations of active materials
AU8317587A (en) Therapeutic preparations
PH20391A (en) Controlled release pharmaceutical preparations
AU572046B2 (en) The injection of implants into animals
AU588828B2 (en) Controlled release capsule
AU5126785A (en) Handling artificial turf
AU6287786A (en) Therapeutic composition
AU549066B2 (en) Preparation of human insulin
AU2554884A (en) Subcutaneous implant of estradiol
AU613543B2 (en) Preparation of halofluorobenzenes
AU4552389A (en) Preparation of n-acyl-aminomethylphosphonates
AU1823588A (en) Novel compounds and their preparations and formulations
AU4802285A (en) Dental implant
AU3050089A (en) Cosmetic preparation
AU2317088A (en) Pacemaker system
AU578500B2 (en) Preparation of optically active azolylcarbinols
AU6407686A (en) Artificial plant
AU566580B2 (en) Preparation of 1-azidoaldoses
IL92279A0 (en) Preparation of 2-chloro-4-toluenesulfonic acid